 |
|
|
July, 31, 2012
| Torii Pharmaceutical Co., Ltd. |
|
|
| Initiation of domestic Phase II/III clinical studies on TO-203, a drug for immunotherapy for house dust mite induced allergic diseases |
|
Torii Pharmaceutical Co., Ltd. (Torii) (TSE:4551) announced the initiation of Phase II/III clinical studies on TO-203, an immunotherapy drug for house dust mite induced allergic diseases.
These are randomized, placebo-controlled, multicenter, double-blind, comparative studies targeting patients with house dust mite induced allergic asthma and rhinitis, respectively. The two studies investigate efficacy and safety of sublingually administered TO-203.
Torii holds the exclusive rights to develop and commercialize TO-203 in Japan, which were licensed from ALK-Abelló A/S in January 2011.
Through providing immunotherapy drugs, Torii makes the efforts to improve the quality of life for allergy patients and meet the medical needs of healthcare professionals.
・Immunotherapy
This is a therapy in which an allergy’s causal allergen is administered, starting at low concentrations and doses, and gradually increasing them to higher doses and concentrations, so as to alleviate the subject’s hypersensitivity to the allergen.
・House dust mite induced allergic asthma and rhinitis
House dust mite induced allergic asthma is a disease in which chronic inflammation occurs in the airways due to allergy to house dust mites. If a patient develops this disease, the airways become narrower than in healthy people and impede the flow of air. This triggers a variety of respiratory symptoms, including coughing, sputum, shortness of breath and wheezing. If the symptoms aggravate, seizure-like symptoms of the respiratory organs may occur.
House dust mite induced allergic rhinitis caused by house dust mites, on the other hand, is a disease in which nasal symptoms such as sneezing, nasal drainage and nasal congestion occur due to allergy to house dust mites.
|
|
|
| |
|
|
|
|
